KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Adaptive Biotechnologies (ADPT) Shares Outstanding (Weighted Average) (2018 - 2025)

Historic Shares Outstanding (Weighted Average) for Adaptive Biotechnologies (ADPT) over the last 8 years, with Q3 2025 value amounting to $152.4 million.

  • Adaptive Biotechnologies' Shares Outstanding (Weighted Average) rose 333.24% to $152.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $152.4 million, marking a year-over-year increase of 333.24%. This contributed to the annual value of $147.1 million for FY2024, which is 188.27% up from last year.
  • Adaptive Biotechnologies' Shares Outstanding (Weighted Average) amounted to $152.4 million in Q3 2025, which was up 333.24% from $152.1 million recorded in Q2 2025.
  • Adaptive Biotechnologies' 5-year Shares Outstanding (Weighted Average) high stood at $152.4 million for Q3 2025, and its period low was $139.0 million during Q1 2021.
  • Moreover, its 5-year median value for Shares Outstanding (Weighted Average) was $144.4 million (2023), whereas its average is $144.7 million.
  • Its Shares Outstanding (Weighted Average) has fluctuated over the past 5 years, first soared by 1024.08% in 2021, then surged by 124.27% in 2023.
  • Quarter analysis of 5 years shows Adaptive Biotechnologies' Shares Outstanding (Weighted Average) stood at $140.4 million in 2021, then rose by 1.54% to $142.5 million in 2022, then grew by 1.31% to $144.4 million in 2023, then increased by 1.88% to $147.1 million in 2024, then increased by 3.62% to $152.4 million in 2025.
  • Its last three reported values are $152.4 million in Q3 2025, $152.1 million for Q2 2025, and $149.2 million during Q1 2025.